Nautilus Biotechnology Valuation
| NAUT Stock | USD 0.99 0.01 1.00% |
Today, the firm appears to be overvalued. Nautilus Biotechnology secures a last-minute Real Value of $0.95 per share. The latest price of the firm is $0.99. Our model forecasts the value of Nautilus Biotechnology from analyzing the firm fundamentals such as Current Valuation of 25.47 M, return on equity of -0.3, and Shares Owned By Insiders of 33.30 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Nautilus Biotechnology's valuation include:
Overvalued
Today
Please note that Nautilus Biotechnology's price fluctuation is extremely dangerous at this time. Calculation of the real value of Nautilus Biotechnology is based on 3 months time horizon. Increasing Nautilus Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Nautilus Biotechnology's intrinsic value may or may not be the same as its current market price of 0.99, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.99 | Real 0.95 | Target 3.44 | Hype 0.99 | Naive 0.97 |
The intrinsic value of Nautilus Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nautilus Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nautilus Biotechnology helps investors to forecast how Nautilus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nautilus Biotechnology more accurately as focusing exclusively on Nautilus Biotechnology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Nautilus Biotechnology's intrinsic value based on its ongoing forecasts of Nautilus Biotechnology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Nautilus Biotechnology's closest peers.
Nautilus Biotechnology Cash |
|
Nautilus Valuation Trend
Nautilus Biotechnology's real value is important for investors to make better decisions and a more accurate overall view of Nautilus Biotechnology's financial worth over time. Using both Nautilus Biotechnology's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Nautilus Biotechnology Total Value Analysis
Nautilus Biotechnology is now anticipated to have valuation of 25.47 M with market capitalization of 124.89 M, debt of 30.48 M, and cash on hands of 299.34 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nautilus Biotechnology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
25.47 M | 124.89 M | 30.48 M | 299.34 M |
Nautilus Biotechnology Asset Utilization
One of the ways to look at asset utilization of Nautilus is to check how much profit was generated for every dollar of assets it reports. Nautilus Biotechnology secures a negative usage of assets of -0.19 %, losing $0.001857 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Nautilus Biotechnology shows how discouraging it operates for each dollar spent on its assets.Nautilus Biotechnology Ownership Allocation
Nautilus Biotechnology maintains a total of 126.15 Million outstanding shares. Nautilus Biotechnology holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nautilus Biotechnology Profitability Analysis
Net Loss for the year was (70.78 M) with profit before overhead, payroll, taxes, and interest of 0.About Nautilus Biotechnology Valuation
The stock valuation mechanism determines Nautilus Biotechnology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Nautilus Biotechnology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nautilus Biotechnology. We calculate exposure to Nautilus Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nautilus Biotechnology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -5.1 M | -5.4 M |
Nautilus Biotechnology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Nautilus Biotechnology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 125.4 M |
Nautilus Biotechnology Current Valuation Indicators
Nautilus Biotechnology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Nautilus Biotechnology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Nautilus Biotechnology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Nautilus Biotechnology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Nautilus Biotechnology's worth.Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.